{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:08:19Z","timestamp":1788782899598,"version":"build-2803163510"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100021812","name":"Sydney Partnership for Health, Education, Research and Enterprise","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001773","name":"University of New South Wales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001773","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021529","name":"The Prince of Wales Hospital Foundation Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021529","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.schres.2026.06.021","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T01:12:40Z","timestamp":1782781960000},"page":"19-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Weight loss and gut microbial changes associated with semaglutide among people living with schizophrenia receiving clozapine or olanzapine: An open-label 24-week semaglutide intervention and 76-week trial"],"prefix":"10.1016","volume":"296","author":[{"given":"Julia M.","family":"Lappin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Bolton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Yi","family":"Chua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Grattan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Samaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordana","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryanne","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Buten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Teasdale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tang","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad","family":"El-Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9701","key":"10.1016\/j.schres.2026.06.021_bb0005","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","article-title":"Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study","volume":"374","author":"Astrup","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.schres.2026.06.021_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting linear mixed-effects models using lme4","volume":"67","author":"Bates","year":"2015","journal-title":"J. Stat. Softw."},{"key":"10.1016\/j.schres.2026.06.021_bb0015","volume":"3 eLife 10","author":"Beghini","year":"2021","journal-title":"Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery"},{"issue":"3","key":"10.1016\/j.schres.2026.06.021_bb0020","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S2213-8587(17)30236-X","article-title":"Progress and challenges in anti-obesity pharmacotherapy","volume":"6","author":"Bessesen","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"11","key":"10.1016\/j.schres.2026.06.021_bb0025","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/s41587-023-01688-w","article-title":"Extending and improving metagenomic taxonomic profiling with uncharacterized species using MetaPhlAn 4","volume":"41","author":"Blanco-M\u00edguez","year":"2023","journal-title":"Nat. Biotechnol."},{"issue":"7","key":"10.1016\/j.schres.2026.06.021_bb0030","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry (Edgmont)"},{"issue":"17","key":"10.1016\/j.schres.2026.06.021_bb0035","doi-asserted-by":"crossref","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","article-title":"Fastp: an ultra-fast all-in-one FASTQ preprocessor","volume":"34","author":"Chen","year":"2018","journal-title":"Bioinformatics"},{"issue":"9","key":"10.1016\/j.schres.2026.06.021_bb0040","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/eip.13508","article-title":"Implementation of a lifestyle and life-skills intervention to prevent weight-gain and cardiometabolic abnormalities in young people with first-episode psychosis as part of routine care: the keeping the body in mind program","volume":"18","author":"Curtis","year":"2024","journal-title":"Early Interv. Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2026.06.021_bb0045","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1017\/S0033291719001399","article-title":"Symptom remission at 12-weeks strongly predicts long-term recovery from the first episode of psychosis","volume":"50","author":"Dazzan","year":"2020","journal-title":"Psychol. Med."},{"issue":"2","key":"10.1016\/j.schres.2026.06.021_bb0050","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs","volume":"8","author":"De Hert","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"issue":"8","key":"10.1016\/j.schres.2026.06.021_bb0055","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S2215-0366(19)30132-4","article-title":"The lancet psychiatry commission: a blueprint for protecting physical health in people with mental illness","volume":"6","author":"Firth","year":"2019","journal-title":"Lancet Psychiatry"},{"issue":"11","key":"10.1016\/j.schres.2026.06.021_bb0060","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1001\/jamapsychiatry.2025.2332","article-title":"Semaglutide treatment of antipsychotic-treated patients with schizophrenia, prediabetes, and obesity: the HISTORI randomized clinical trial","volume":"82","author":"Ganeshalingam","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2026.06.021_bb0065","first-page":"308","article-title":"The human gut microbiota: metabolism and perspective in obesity","volume":"9","author":"Gomes","year":"2018","journal-title":"Gut Microbes"},{"issue":"4","key":"10.1016\/j.schres.2026.06.021_bb0070","first-page":"443","article-title":"Comparative efficacy and tolerability of 32 Oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network Meta-analysis","volume":"18","author":"Huhn","year":"2020","journal-title":"Focus (Am Psychiatr Publ)"},{"issue":"6","key":"10.1016\/j.schres.2026.06.021_bb0075","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1038\/s41396-019-0364-5","article-title":"Defining the role of Parasutterella, a previously uncharacterized member of the core gut microbiota","volume":"13","author":"Ju","year":"2019","journal-title":"ISME J."},{"issue":"9","key":"10.1016\/j.schres.2026.06.021_bb0080","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.2337\/db17-0067","article-title":"Hypothalamic inflammation in human obesity is mediated by environmental and genetic factors","volume":"66","author":"Kreutzer","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.schres.2026.06.021_bb0085","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.schres.2018.02.035","article-title":"Cardio-metabolic risk and its management in a cohort of clozapine-treated outpatients","volume":"199","author":"Lappin","year":"2018","journal-title":"Schizophr. Res."},{"issue":"7","key":"10.1016\/j.schres.2026.06.021_bb0090","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/jamapsychiatry.2017.1220","article-title":"Effect of Liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia Spectrum disorder: a randomized clinical trial","volume":"74","author":"Larsen","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2026.06.021_bb0095","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1017\/S1092852918001311","article-title":"High prevalence of prediabetes and metabolic abnormalities in overweight or obese schizophrenia patients treated with clozapine or olanzapine","volume":"24","author":"Larsen","year":"2019","journal-title":"CNS Spectr."},{"issue":"18","key":"10.1016\/j.schres.2026.06.021_bb0100","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1093\/bioinformatics\/bty191","article-title":"Minimap2: pairwise alignment for nucleotide sequences","volume":"34","author":"Li","year":"2018","journal-title":"Bioinformatics"},{"issue":"3","key":"10.1016\/j.schres.2026.06.021_bb0105","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s00125-021-05609-x","article-title":"Prevalence of type 2 diabetes in psychiatric disorders: an umbrella review with meta-analysis of 245 observational studies from 32 systematic reviews","volume":"65","author":"Lindekilde","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.schres.2026.06.021_bb0110","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1146\/annurev-pharmtox-010919-023628","article-title":"Microbiota-gut-brain Axis: new therapeutic opportunities","volume":"60","author":"Long-Smith","year":"2020","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"11","key":"10.1016\/j.schres.2026.06.021_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1009442","article-title":"Multivariable association discovery in population-scale meta-omics studies","volume":"17","author":"Mallick","year":"2021","journal-title":"PLoS Comput. Biol."},{"issue":"1","key":"10.1016\/j.schres.2026.06.021_bb0120","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.eurpsy.2005.09.009","article-title":"Meta-analysis of drop-out rates in randomised clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia","volume":"21","author":"Martin","year":"2006","journal-title":"Eur. Psychiatry"},{"issue":"18","key":"10.1016\/j.schres.2026.06.021_bb0125","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1056\/NEJMoa1915784","article-title":"Association between mental disorders and subsequent medical conditions","volume":"382","author":"Momen","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.schres.2026.06.021_bb0130","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1001\/jamapsychiatry.2022.0347","article-title":"Mortality associated with mental disorders and comorbid general medical conditions","volume":"79","author":"Momen","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.schres.2026.06.021_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2019.112606","article-title":"Cardio-metabolic risk in individuals prescribed long-acting injectable antipsychotic medication","volume":"281","author":"Morell","year":"2019","journal-title":"Psychiatry Res."},{"issue":"11","key":"10.1016\/j.schres.2026.06.021_bb0140","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1001\/2012.jama.11132","article-title":"Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults","volume":"308","author":"Neeland","year":"2012","journal-title":"Jama"},{"key":"10.1016\/j.schres.2026.06.021_bb0145","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jpsychires.2018.01.013","article-title":"Overview and systematic review of studies of microbiome in schizophrenia and bipolar disorder","volume":"99","author":"Nguyen","year":"2018","journal-title":"J. Psychiatr. Res."},{"issue":"11","key":"10.1016\/j.schres.2026.06.021_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens11111279","article-title":"The role of the microbiome in the metabolic health of people with schizophrenia and related psychoses: cross-sectional and pre-post lifestyle intervention analyses","volume":"11","author":"O\u2019Donnell","year":"2022","journal-title":"Pathogens"},{"key":"10.1016\/j.schres.2026.06.021_bb0155","series-title":"Vegan: Community Ecology Package","author":"Oksanen","year":"2022"},{"issue":"10148","key":"10.1016\/j.schres.2026.06.021_bb0160","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O\u2019Neil","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.schres.2026.06.021_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11030669","article-title":"Effect of glucagon-like Peptide-1 receptor agonists on cardio-metabolic risk factors among obese\/overweight individuals treated with antipsychotic drug classes: an updated systematic review and Meta-analysis of randomized controlled trials","volume":"11","author":"Patoulias","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.schres.2026.06.021_bb0170","series-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2024"},{"issue":"4","key":"10.1016\/j.schres.2026.06.021_bb0175","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3920\/BM2014.0104","article-title":"Gut microbiota composition correlates with changes in body fat content due to weight loss","volume":"6","author":"Remely","year":"2015","journal-title":"Benefic. Microbes"},{"issue":"9","key":"10.1016\/j.schres.2026.06.021_bb0180","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs Tirzepatide for weight loss in adults with overweight or obesity","volume":"184","author":"Rodriguez","year":"2024","journal-title":"JAMA Intern. Med."},{"issue":"14","key":"10.1016\/j.schres.2026.06.021_bb0185","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous Semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"Jama"},{"issue":"2","key":"10.1016\/j.schres.2026.06.021_bb0190","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1001\/jamapsychiatry.2025.3639","article-title":"Semaglutide and early-stage metabolic abnormalities in individuals with schizophrenia spectrum disorders: a randomized clinical trial","volume":"83","author":"Sass","year":"2026","journal-title":"JAMA Psychiatry"},{"issue":"10434","key":"10.1016\/j.schres.2026.06.021_bb0195","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S0140-6736(24)00351-9","article-title":"Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials","volume":"403","author":"Shi","year":"2024","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.schres.2026.06.021_bb0200","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.tibtech.2015.06.011","article-title":"Proteobacteria: microbial signature of dysbiosis in gut microbiota","volume":"33","author":"Shin","year":"2015","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.schres.2026.06.021_bb0205","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jpsychires.2020.02.015","article-title":"Metabolic measures 12 months after a randomised controlled trial of treatment of clozapine associated obesity and diabetes with exenatide (CODEX)","volume":"124","author":"Siskind","year":"2020","journal-title":"J. Psychiatr. Res."},{"issue":"7","key":"10.1016\/j.schres.2026.06.021_bb0210","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S2215-0366(25)00129-4","article-title":"Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-Centre, participant and investigator- blinded, randomised controlled trial in Australia","volume":"12","author":"Siskind","year":"2025","journal-title":"Lancet Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2026.06.021_bb0215","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1111\/dom.13167","article-title":"Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: a randomized controlled trial (CODEX)","volume":"20","author":"Siskind","year":"2018","journal-title":"Diabetes Obes. Metab."},{"issue":"12","key":"10.1016\/j.schres.2026.06.021_bb0220","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1007\/s00125-008-1152-3","article-title":"Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat","volume":"51","author":"Smith","year":"2008","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.schres.2026.06.021_bb0225","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.schres.2009.07.011","article-title":"Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour","volume":"115","author":"Smith","year":"2009","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.schres.2026.06.021_bb0230","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3109\/13813455.2011.576681","article-title":"Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat","volume":"117","author":"Smith","year":"2011","journal-title":"Arch. Physiol. Biochem."},{"issue":"1\u20133","key":"10.1016\/j.schres.2026.06.021_bb0235","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.schres.2014.05.003","article-title":"Clozapine directly increases insulin and glucagon secretion from islets: implications for impairment of glucose tolerance","volume":"157","author":"Smith","year":"2014","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2026.06.021_bb0240","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/acps.12982","article-title":"One-year follow-up on liraglutide treatment for prediabetes and overweight\/obesity in clozapine- or olanzapine-treated patients","volume":"139","author":"Svensson","year":"2019","journal-title":"Acta Psychiatr. Scand."},{"issue":"1\u20133","key":"10.1016\/j.schres.2026.06.021_bb0245","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.schres.2010.04.003","article-title":"Meta-analysis of rates of drop-out from psychosocial treatment among persons with schizophrenia spectrum disorder","volume":"121","author":"Villeneuve","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2026.06.021_bb0250","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2025-085304","article-title":"Weight regain after cessation of medication for weight management: systematic review and meta-analysis","volume":"392","author":"West","year":"2026","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.schres.2026.06.021_bb0255","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/dom.14334","article-title":"The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: results of a pilot randomized, double-blind, placebo-controlled trial","volume":"23","author":"Whicher","year":"2021","journal-title":"Diabetes Obes. Metab."},{"issue":"11","key":"10.1016\/j.schres.2026.06.021_bb0260","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly Semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.schres.2026.06.021_bb0265","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.schres.2026.06.021_bb0270","series-title":"ICD-11: International Classification of Diseases (11th Revision)","author":"World Health Organization","year":"2022"},{"issue":"3","key":"10.1016\/j.schres.2026.06.021_bb0275","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","article-title":"Mapping the effectiveness and risks of GLP-1 receptor agonists","volume":"31","author":"Xie","year":"2025","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.schres.2026.06.021_bb0280","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1038\/ismej.2012.27","article-title":"Structural resilience of the gut microbiota in adult mice under high-fat dietary perturbations","volume":"6","author":"Zhang","year":"2012","journal-title":"ISME J."},{"key":"10.1016\/j.schres.2026.06.021_bb0285","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/s41398-025-03449-6","article-title":"Multi-kingdom microbial changes and their associations with the clinical characteristics in schizophrenia patients","volume":"15","author":"Zhu","year":"2025","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.schres.2026.06.021_bb0290","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.schres.2025.04.017","article-title":"Exploring the relationship between the gut microbiota and cognitive function in schizophrenia patients with distinct weights","volume":"280","author":"Zhu","year":"2025","journal-title":"Schizophr. Res."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996426002045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996426002045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:19:20Z","timestamp":1788779960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996426002045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":58,"alternative-id":["S0920996426002045"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2026.06.021","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Weight loss and gut microbial changes associated with semaglutide among people living with schizophrenia receiving clozapine or olanzapine: An open-label 24-week semaglutide intervention and 76-week trial","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2026.06.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}